Journal
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
Volume 17, Issue 2, Pages 166-169Publisher
ELSEVIER SCIENCE INC
DOI: 10.1097/JGP.0b013e318187de18
Keywords
Alzheimer; sleep; agitation; melatonin; dementia
Categories
Funding
- NIA [AG08415, P50 AG05131, K23 AG028452]
- Research Service of the Veterans Affairs San Diego Healthcare System
Ask authors/readers for more resources
Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation. Design: Randomized, placebo-controlled study. Setting: Nursing homes in San Diego, CA, metropolitan area. Participants: Subjects were patients with probable Alzheimer disease. Intervention: Melatonin (8.5 mg immediate release and 1.5 mg sustained release) (N = 24) or placebo (N = 17) administered at 10: 00 P. M. for 10 consecutive nights. The protocol consisted of baseline (3 days), treatment (10 days), and posttreatment (5 days) phases. Measurements: Sleep was measured continuously using actigraphy. Agitation was rated using both the Agitated Behavior Rating Scale and the Cohen-Mansfield Agitation Inventory. Treatment effects were examined both across the 24-hr day and separately by nursing shift. Results: There were no significant effects of melatonin, compared with placebo, on sleep, circadian rhythms, or agitation. Conclusion: This study failed to find a beneficial effect of exogenous melatonin, consistent with a number of other studies. The lack of efficacy may be related to the absence of a true treatment effect or to the superphysiologic dose of melatonin used. (Am J Geriatr Psychiatry 2009; 17:166-169)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available